Shionogi & Company Limited

Shionogi Seiyaku Kabushiki Kaisha

D. Western Therapeutics Institute, Inc.

Shionogi Company Limited

Nobuhiro Haga

Susumu Kamata

Masanao Inagaki

Yoshinori Tamura

Kaoru Seno

Sanji Hagishita

Tatsuo Tsuri

Tsuyoshi Hasegawa

Shin-ichiro Hara

Yoshihisa Goto

Shinichi Oda

Takeaki Matsui

Mitsuaki Ohtani

Kenji Morimoto

Fumihiko Watanabe

Saichi Matsumoto

Kenji Kawada

Tadahiko Tsushima

Kouichi Noguchi

Masayuki Narisada

Hirokuni Jyoyama

Kimio Takahashi

Morio Kishi

Toshihiko Okada

Takeshi Shiota

Yasunobu Ishihara

Yasushi Hasegawa

Wataru Nagata

Toshiro Konoike

Norihiko Tanimoto

Makoto Takahagi

Yasushi Murakami

Sohei Omura

Sanji Hagashita

Atsushi Inoue

Shin-Ichiro c/o Shionogi & Co Ltd 12-4 Hara

Tsuyoshi c/o Shionogi & Co Ltd 12-4 Hasegawa

Yoshinori c/o Shionogi & Co Ltd 12-4 Tamura

Yoshihisa c/o Shionogi & Co Ltd 1-3 Goto

Masanao c/o Shionogi & Co Ltd 12-4 Inagaki

A composition containing Brilliant Blue G (BBG) or a pharmaceutically acceptable salt thereof, and a positional isomer of Brilliant Blue G (BBG) or a pharmaceutically acceptable salt thereof, the composition containing 90 wt % or more and 100 wt % or less of one or both of Brilliant Blue G (BBG) and the pharmaceutically acceptable salt thereof in the total of the Brilliant Blue G (BBG), the pharmaceutically acceptable salt of Brilliant Blue G (BBG), the positional isomer of Brilliant Blue G (BBG), and the pharmaceutically acceptable salt of the positional isomer of Brilliant Blue G (BBG), a method for producing said composition, and a method of removing the ocular membrane of a human patient.

Triaryl methane composition, dye composition for ocular membrane dyeing

Stable crystalline forms of a compound represented by the formula (IA): an acid addition salt, and/or a solvate thereof are provided by the present invention. Said crystalline forms are extremely useful as materials for preparing medicines. Novel processes for preparing 6,7-unsaturated-7-carbamoyl morphinan derivatives are also provided by the present invention.

Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same

A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation. A compound represented by the formula (I): wherein Rand Rare each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted cycloalkyl, optionally substituted aryl etc., Ris hydrogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy etc., Ris hydrogen or lower alkyl, Ris hydrogen, lower alkyl, cycloalkyl lower alkyl or lower alkenyl,or a pharmaceuticallyacceptablyacceptablesalt, or a solvate thereof is provided.

6,7-unsaturated-7-carbamoyl substituted morphinan derivative

A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation. A compound represented by the formula (I):

A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation. A compound represented by the formula (I): wherein Rand Rare each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted cycloalkyl, optionally substituted aryl etc., Ris hydrogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy etc., Ris hydrogen or lower alkyl, Ris hydrogen, lower alkyl, cycloalkyl lower alkyl or lower alkenyl,or a pharmaceutically acceptably salt, or a solvate thereof is provided.

Tricyclic compound

Benzodiazepine derivative

Carbamoylmethylurea derivatives

A selective and high-yield method is described for producing stereoisomeric benzylidene derivatives of the formula III: ##STR1## wherein R.sup.1 and R.sup.2 each independently is lower alkyl, lower alkoxy or halogen; Y is SO.sub.2, SO or CO; --A-- is optionally substituted lower alkylene; --B-- is --CH.sub.2 -- or --O--; or --A-- and --B-- taken together may form optionally substituted phenylene or optionally substituted lower alkenylene; and R is hydrogen, optionally substituted lower alkyl, cycloalkyl, lower alkoxy, hydroxy, optionally substituted aryl, optionally substituted arylalkyl; optionally substituted arylalkyloxy, heterocyclic ring or N-protecting groups, which comprises reacting a compound of the formula I: ##STR2## wherein R.sup.1 and R.sup.2 are as defined above and X is lower alkoxy or halogen with a compound of the formula II: ##STR3## wherein Y, --A--, --B-- and R are as defined above in the presence of a base.

Method for producing benzylidene derivatives

The present invention relates to novel 3-benzylidene-1-carbamoyl-2-pyrroridone analogues having advantage anti-inflammatory activities, which is represented by the formula: ##STR1## wherein R.sup.1 and R.sup.2 each is independently hydrogen, alkyl, alkoxy, or halogen; R.sup.3 is hydrogen or acyl; R.sup.4 is hydrogen, alkyl, hydroxy, alkoxy, cyano, or halogen; R.sup.5 and R.sup.6 each is independently hydrogen, alkyl, aryl, aralkyl, heterocyclic group, substituted or unsubstituted amino, or OR.sup.7 wherein R.sup.7 is hydrogen, alkyl, aryl, acyl, or aralkyl, or taken together with the adjacent nitrogen atom may form heterocyclic group which may contain N, O, and/or S, and X and Y each is independently O, S, substituted or unsubstituted imino, or substituted or unsubstituted methylene. In more detail, the present invention provides an anti-inflammatory agent which is useful for the treatment of chronic inflammation and has little side effect, e.g., stomach disease.

3-benzylidene-1-carbamoyl-2-pyrrolidone analogues

Growing community of inventors

Osaka, Japan

Nobuhiro Haga